Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
By B. Eriksson, L. Borris, R. Friedman, S. Haas, M. Huisman, A. Kakkar, T. Bandel, H. Beckmann, E. Muehlhofer, F. Misselwitz and 1 more. New England Journal of Medicine, 2008
1,470 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/57025a04416ab1f1441996e1321ce05b2197cef3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. (2018, positive): “14 Low dose rivaroxaban prevents venous thromboembolism after orthopaedic surgery, 15 and the Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-2) trial 16 showed that low-dose rivaroxaban (2·5 mg twice a day) used in addition to dual antiplatelet therapy reduced major adverse…”